Evogene
EVGN
22 hedge funds and large institutions have $44.5M invested in Evogene in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
13% more capital invested
Capital invested by funds: $39.3M → $44.5M (+$5.23M)
0.4% more ownership
Funds ownership: 30.24% → 30.63% (+0.4%)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.18M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$503K |
| 3 |
JP Morgan Chase
New York
|
+$445K |
| 4 |
MCM
Moon Capital Management
New York
|
+$262K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$1.36M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$803K |
| 3 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
-$80.2K |
| 4 |
Morgan Stanley
New York
|
-$14.3K |
| 5 |
SWM
Stockman Wealth Management
Billings,
Montana
|
-$7.81K |
EVGN Hedge Fund Activity: Q1 2017 in Review
22 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2017, worth a combined $44.5M — up 13% from $39.3M a quarter earlier.
Fund positioning in EVGN was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 8 added to existing stakes and 4 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $1.18M. The largest seller was Waddell & Reed Financial, cutting an estimated $1.36M.
- 22 institutional investors held Evogene (EVGN) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $44.5M of Evogene stock for Q1 2017, up 13% quarter-over-quarter.
- 1 fund opened new Evogene positions in Q1 2017 and 1 closed out, a net change of 0 holders.
- The largest Evogene buyer in Q1 2017 was Goldman Sachs, an estimated $1.18M added.
- The largest Evogene seller in Q1 2017 was Waddell & Reed Financial, an estimated $1.36M sold.
Based on aggregated 13F filings for Q1 2017.